Primary reference | Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-mutant Pancreatic and Colorectal Cancer., Weisner J, Landel I, Reintjes C, Uhlenbrock N, Trajkovic-Arsic M, Dienstbier N, Hardick J, Ladigan S, Lindemann M, Smith S, Quambusch L, Scheinpflug R, Depta L, Gontla R, Unger A, Muller H, Baumann M, Schultz-Fademrecht C, Gunther G, Maghnouj A, Muller MP, Pohl M, Teschendorf C, Wolters H, Viebahn R, Tannapfel A, Uhl W, Hengstler JG, Hahn SA, Siveke JT, Rauh D, Cancer Res. 2019 Mar 11. pii: 0008-5472.CAN-18-2861. doi:, 10.1158/0008-5472.CAN-18-2861. PMID:30858154 |